Drug intelligence / Profile preview

ABD-0171

Development stage: Preclinical
Lead developer: Advanced BioDesign
Modality: Small Molecules

Overview

ABD-0171 is a second-generation small molecule inhibitor of aldehyde dehydrogenase (ALDH) currently in preclinical development by Advanced BioDesign. ALDH enzymes are known to be overexpressed in cancer stem cells (CSCs), where they contribute to metabolic plasticity, detoxification of reactive aldehydes, and resistance to conventional therapies. By inhibiting ALDH, ABD-0171 aims to deplete the CSC population and sensitize tumors to other treatments. The compound is specifically being investigated for the treatment of solid tumors, with a strategic focus on its use in combination with anti-PD-1 immune checkpoint inhibitors to overcome immune evasion and enhance therapeutic efficacy.

Targets

ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)ALDH1A2 (Aldehyde dehydrogenase 1 family member A2)ALDH1A3 (Aldehyde dehydrogenase 1 family member A3)

Beyond the preview

Go deeper on ABD-0171.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABD-0171.